Cardiff Oncology, Inc. (CRDF)

Over the past six months, Cardiff Oncology's stock price has experienced notable fluctuations. As of November 26, 2025, the share price was $2.34, representing a decline of 7.87% from November 27, 2024. The stock was trading at $4.34 at the beginning of 2025 and has since decreased by 46.1% to $2.34. Key events impacting the stock include positive data from the Phase 2 CRDF-004 trial, the report of Q2 and Q3 2025 losses, a 42% price drop in July 2025, an insider buying report, positive Phase 2 CRDF-004 data showing a 19% improvement, the report of approximately $60.6 million in cash and investments as of September 30, 2025, projecting a cash runway into Q1 2027, and an 11% stock drop in November 2025.

As a clinical-stage biotechnology company, Cardiff Oncology's revenue generation is primarily through licensing agreements and collaborations, which are not typically subject to seasonal demand fluctuations. The demand for its drug candidates is driven by unmet medical needs in oncology and the progress and success of its clinical development programs.

Cardiff Oncology, Inc. (CRDF) is a clinical-stage biotechnology company focused on developing novel cancer therapies, operating within the biotechnology and pharmaceutical industries with a focus on precision oncology and biomarker-driven drug development. Their lead drug candidate, Onvansertib, is being evaluated in combination therapies for various cancer types. The company's business model revolves around research, development, and potential commercialization through licensing agreements and collaborations.

Cardiff Oncology, Inc. primarily operates within the United States, with its headquarters located in San Diego, California.

Cardiff Oncology's brand reputation has been shaped by its clinical trial progress and financial performance. The company has received a consensus rating of "Buy" or "Moderate Buy" from analysts. Positive events include positive Phase 2 trial results for Onvansertib, expansion of clinical trials, and a new U.S. patent. However, the brand reputation has been negatively impacted by a decline in the overall response rate, stock price decreases, and a projected net loss.

Cardiff Oncology (NASDAQ: CRDF) has a diverse ownership structure. Institutional shareholders own approximately 37.34% to 43.00% of the company, while insiders hold around 4.37% to 26.00%, and retail investors own a significant portion, ranging from 36.66% to 76.82%. Major institutional owners include BlackRock, Inc., Vanguard Group Inc., Laurion Capital Management LP, Pfizer Inc., Blair William & Co/il, Acorn Capital Advisors, LLC, Geode Capital Management, LLC, and State Street Corp. Robert Merrill Hunter is the largest individual shareholder, owning 5.07 million shares, representing 7.52% of the company.